{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:46:48Z","timestamp":1784634408885,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100003161","name":"National Alopecia Areata Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003161","name":"National Alopecia Areata Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R13AR074890"],"award-info":[{"award-number":["R13AR074890"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidsponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jisp.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T05:10:27Z","timestamp":1603257027000},"page":"S31-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["JAK Inhibitors for the Treatment of Pediatric Alopecia Areata"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-1735","authenticated-orcid":false,"given":"Claire E.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-7691","authenticated-orcid":false,"given":"Brittany G.","family":"Craiglow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jisp.2020.04.005_bib1","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A\u00a0child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jisp.2020.04.005_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/j.jisp.2020.04.005_bib3","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s41409-019-0488-2","article-title":"Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required","volume":"54","author":"Bauters","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jisp.2020.04.005_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/jdv.12315","article-title":"Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata","volume":"28","author":"Bilgi\u00e7","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jisp.2020.04.005_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jisp.2020.04.005_bib7","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib8","first-page":"914","article-title":"An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review","volume":"17","author":"Brown","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2016.11.038","article-title":"Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis","volume":"76","author":"Castelo-Soccio","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220377","article-title":"Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome","volume":"2017","author":"Coskun","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jisp.2020.04.005_bib11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jdcr.2018.07.018","article-title":"Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes","volume":"4","author":"Craiglow","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jisp.2020.04.005_bib12","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2018.08.041","article-title":"Tofacitinib for the treatment of alopecia areata in preadolescent children","volume":"80","author":"Craiglow","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaad.2018.12.041","article-title":"Tofacitinib therapy for children with severe alopecia areata","volume":"80","author":"Dai","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2230.1989.tb02604.x","article-title":"Juvenile versus maturity-onset\u00a0alopecia areata--a comparative retrospective clinical study","volume":"14","author":"De Waard-van der Spek","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib19","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jisp.2020.04.005_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jisp.2020.04.005_bib21","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fr\u00e9mond","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jisp.2020.04.005_bib22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","article-title":"Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history","volume":"20","author":"Goh","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jisp.2020.04.005_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.25376","article-title":"Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results","volume":"94","author":"Gonz\u00e1lez Vicent","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jisp.2020.04.005_bib24","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2014.108142","article-title":"A\u00a0unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy","volume":"99","author":"Hanna","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jisp.2020.04.005_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib27","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jisp.2020.04.005_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","article-title":"Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jisp.2020.04.005_bib29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jisp.2020.04.005_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1468-3083.2008.02956.x","article-title":"Alopecia areata prevalence by gender and age","volume":"23","author":"Kyriakis","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jisp.2020.04.005_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib32","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaad.2018.11.037","article-title":"Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","article-title":"Ruxolitinib for the treatment of severe alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A\u00a0phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jisp.2020.04.005_bib36","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jisp.2020.04.005_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26328","article-title":"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jisp.2020.04.005_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archderm.1963.01590210048007","article-title":"Alopecia areata. An evaluation of 736 patients","volume":"88","author":"Muller","year":"1963","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib39","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jisp.2020.04.005_bib40","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","article-title":"Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series","volume":"77","author":"Park","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1203475418760512","article-title":"A\u00a0case report highlighting the effective treatment of alopecia universalis with tofacitinib\u00a0in an adolescent and adult patient","volume":"22","author":"Patel","year":"2018","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jisp.2020.04.005_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40272-017-0239-z","article-title":"Alopecia areata: an update on treatment options for children","volume":"19","author":"Peloquin","year":"2017","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jisp.2020.04.005_bib43","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jisp.2020.04.005_bib44","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","article-title":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","volume":"78","author":"Putterman","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib45","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaad.2018.12.051","article-title":"Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study","volume":"80","author":"Putterman","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jisp.2020.04.005_bib47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archderm.1992.01680150136027","article-title":"Prevalence of alopecia areata in the first National Health and Nutrition Examination Survey","volume":"128","author":"Safavi","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4065\/70.7.628","article-title":"Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jisp.2020.04.005_bib49","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3389\/fimmu.2018.01535","article-title":"A\u00a0mutation outside the dimerization domain causing atypical STING-associated vasculopathy with onset in infancy","volume":"9","author":"Saldanha","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jisp.2020.04.005_bib50","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of\u00a0autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jisp.2020.04.005_bib51","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41409-019-0450-3","article-title":"Ruxolitinib is an effective steroid sparing agent in children with steroid refractory\/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation","volume":"54","author":"Schoettler","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jisp.2020.04.005_bib52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-4362.1992.tb03932.x","article-title":"Profile of alopecia areata: a questionnaire analysis of patient and family","volume":"31","author":"Shellow","year":"1992","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib54","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","article-title":"The pattern and profile of alopecia areata in Singapore--a study of 219 Asians","volume":"41","author":"Tan","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib55","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1525-1470.2006.00161.x","article-title":"The epidemiology of childhood alopecia areata in China: a study of 226 patients","volume":"23","author":"Xiao","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jisp.2020.04.005_bib57","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"}],"container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002420300058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002420300058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:21:10Z","timestamp":1761067270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1087002420300058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1087002420300058"],"URL":"https:\/\/doi.org\/10.1016\/j.jisp.2020.04.005","relation":{},"ISSN":["1087-0024"],"issn-type":[{"value":"1087-0024","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK Inhibitors for the Treatment of Pediatric Alopecia Areata","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology Symposium Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jisp.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}